Table 2. Comparison of laboratory findings at baseline and follow-up period between non-CR and CR groups.
| Biomarkers (unit) | Whole patients |
Male patients |
||
|---|---|---|---|---|
| Non-CR (n = 15) | CR (n = 69) | Non-CR (n = 13) | CR (n = 57) | |
| LDL-C (mg/dL) | ||||
| baseline | 131.7 ± 42.9 | 127.5 ± 35.9 | 134.2 ± 40.0 | 126.6 ± 35.5 |
| follow-up | 94.8 ± 36.2§§ | 82.0 ± 19.2§§§ | 98.8 ± 36.5§§ | 82.6 ± 17.7*§§§ |
| Non-HDL-C (mg/dL) | ||||
| baseline | 150.8 ± 44.0 | 150.7 ± 38.8 | 153.4 ± 41.2 | 146.9 ± 36.9 |
| follow-up | 122.1 ± 44.1§ | 103.6 ± 21.0*§§§ | 126.7 ± 44.9§ | 103.4 ± 19.4*§§§ |
| TG (mg/dL) | ||||
| baseline | 120.2 ± 74.3 | 132.9 ± 85.5 | 118.6 ± 74.7 | 126.0 ± 66.3 |
| follow-up | 172.1 ± 101.1 | 115.6 ± 44.7* | 176.8 ± 103.7 | 115.2 ± 44.8* |
| MDA-LDL (U/L) | ||||
| baseline | 161.5 ± 60.9 | 157.2 ± 61.2 (66) | 163.6 ± 58.8 | 153.7 ± 53.3 (55) |
| follow-up | 126.4 ± 44.9 (14) | 107.4 ± 32.2§§§ | 130.8 ± 46.3 (12) | 108.4 ± 31.9*§§§ |
| RLP-C (mg/dL) | ||||
| baseline | 5.3 ± 2.9 | 6.4 ± 5.1 | 5.5 ± 2.9 | 5.6 ± 2.8 |
| follow-up | 6.3 ± 4.9 | 3.7 ± 1.6*§§§ | 6.7 ± 5.1 | 3.8 ± 1.7*§§§ |
| ApoB (mg/dL) | ||||
| baseline | 101.8 ± 28.9 | 103.9 ± 25.0 | 103.2 ± 27.7 | 102.8 ± 24.3 |
| follow-up | 86.3 ± 29.7§ | 74.6 ± 14.9*§§§ | 89.5 ± 30.2 | 74.4 ± 14.0*§§§ |
| HDL-C (mg/dL) | ||||
| baseline | 46.0 ± 10.5 | 44.9 ± 10.2 | 46.8 ± 11.1 | 44.1 ± 9.8 |
| follow-up | 42.7 ± 7.9 | 46.2 ± 9.4 | 42.1 ± 6.9 | 44.8 ± 9.0 |
| ApoA-I (mg/dL) | ||||
| baseline | 123.9 ± 18.2 | 121.1 ± 20.7 | 125.1 ± 19.4 | 119.3 ± 20.1 |
| follow-up | 123.0 ± 18.2 | 125.9 ± 18.6§ | 122.6 ± 16.4 | 123.0 ± 17.7 |
| CEC (relative value) | ||||
| baseline | 0.88 ± 0.14 | 0.87 ± 0.15 | 0.89 ± 0.13 | 0.87 ± 0.15 |
| follow-up | 0.89 ± 0.13 | 0.96 ± 0.18§§ | 0.91 ± 0.13 | 0.94 ± 0.16§§ |
| AREA (U/L) | ||||
| baseline | 685.3 ± 139.3 (12) | 768.0 ± 169.7 (60) | 675.8 ± 142.0 (11) | 755.8 ± 166.3 (50) |
| follow-up | 750.8 ± 291.3 (12) | 783.6 ± 167.5 (60) | 739.5 ± 302.8 (11) | 773.1 ± 160.2 (50) |
| HbA1c (%) | ||||
| baseline | 6.34 ± 1.48 | 6.28 ± 1.41 | 6.35 ± 1.59 | 6.25 ± 1.40 |
| follow-up | 6.17 ± 0.79 | 6.09 ± 0.62 | 6.16 ± 0.85 | 6.08 ± 0.61 |
| hsCRP (mg/dL) | ||||
| baseline | 0.97 ± 2.35 | 0.90 ± 2.15 | 1.10 ± 2.50 | 1.07 ± 2.33 |
| follow-up | 0.13 ± 0.28 | 0.12 ± 0.27§§ | 0.15 ± 0.30 | 0.13 ± 0.30§§ |
| BNP (pg/mL) | ||||
| baseline | 120.5 ± 134.0 | 101.8 ± 133.3 | 101.5 ± 113.6 | 100.7 ± 122.0 |
| follow-up | 58.2 ± 69.7 (14) | 64.5 ± 58.4§ (64) | 57.8 ± 73.5 (12) | 61.9 ± 57.9§ (52) |
| eGFR (ml/min/1.73 m2) | ||||
| baseline | 86.3 ± 19.7 | 71.8 ± 23.0* | 88.2 ± 20.5 | 72.6 ± 20.4* |
| follow-up | 74.8 ± 15.8§§ | 64.6 ± 18.2*§§§ | 77.2 ± 15.8§ | 65.6 ± 16.6*§§§ |
Data are expressed as mean ± SD. The number in parenthesis indicates actual number of analyzed cases. Seven samples at baseline in CR group were collected in fasting-state at the beginning of CR. The others were collected immediate before the emergency coronary angiography on admission. *p < 0.05 compared with non-CR group by student's t-test. §p< 0.05, §§ p < 0.01, §§§ p < 0.0001 compared with the baseline levels by paired t-test. Abbreviations as in text.